Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MN-221 (Dose Group 1), Bedoradrine Sulfate
MN-221 · 4 trials · 2 indications
The recording of AEs will start after the subject has signed the consent form and will end at the Hour 24 phone interview. Investigator(s) will monitor each subject closely for AEs and the Investigator will record all observed or volunteered AEs.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min \[600 μg\] + 13.3 μg/min for 45 min \[600 μg\]) as an adjunct to the standard of care for acute exacerbation of asthma. |
| Placebo | PLACEBO_COMPARATOR | Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221. |
| MN-221 | EXPERIMENTAL | - |
| MN-221 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MN-221 | DRUG | Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo. |
| Placebo | DRUG | - |
| MN-221 (Dose Group 1) | DRUG | i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour |
| MN-221 (Dose Group 2) | DRUG | i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour |
| MN-221 (Dose Group 3) | DRUG | i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour |
Inclusion Criteria: * Subjects meeting all of the following criteria will be considered for admission to the study: 1. Male or female 18 to 65 years of age, inclusive; 2. Self-reported history of physician-diagnosed and treated asthma for ≥ 3 months prior to randomization; 3. A diagnosis of ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MN-221 is an investigational small molecule being studied for respiratory conditions, specifically asthma and chronic obstructive pulmonary disease (COPD). It has been evaluated both as an adjunct to standard therapy during acute asthma exacerbations and for safety in patients with stable moderate to severe COPD.
MN-221 is being developed by MediciNova, Inc., a biopharmaceutical company that trades under the ticker symbol MNOV. MediciNova has sponsored the clinical trial programs evaluating MN-221 in asthma and COPD patient populations in the United States.
MN-221 is in Phase 2 clinical development. It has completed Phase 2 trials in asthma and Phase 1 trials in COPD. MN-221 is investigational and has not been approved by the FDA for any indication.
MN-221 has been studied in completed trials including NCT00838591 and NCT00679263 in asthma, and NCT01551316 and NCT01013142 in COPD. These trials enrolled a combined total of 260 participants across the asthma and COPD programs.
Yes, MN-221 (Dose Group 1) refers to a specific dose cohort within the MN-221 clinical development program. MN-221 is the base compound name, and Dose Group 1 identifies a particular dosing arm studied in its trials.